Company news

Odyssey Therapeutics, Inc. news

Latest news releases, newest first.

View company

Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026

October 20, 2026

Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026

October 12, 2026

Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026

October 6, 2026

Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum

September 16, 2026

Odyssey Therapeutics to Participate in Upcoming Investor Conferences

August 26, 2026

Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 4, 2026

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

June 17, 2026

Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering

May 7, 2026

Decks